PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/00, 38/24 — A1

(11) International Publication Number: **WO 00/04913**

(43) International Publication Date: 3 February 2000 (03.02.00)

(21) International Application Number: PCT/US99/16031

(22) International Filing Date: 15 July 1999 (15.07.99)

(30) Priority Data:

60/093,906	23 July 1998 (23.07.98)	US
60/094,611	30 July 1998 (30.07.98)	US
60/094,767	31 July 1998 (31.07.98)	US
60/098,711	1 September 1998 (01.09.98)	US
60/100,696	17 September 1998 (17.09.98)	US

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HOFFMANN, James, Arthur [US/US]; 4272 Woodland Streams Drive, Greenwood, IN 46143 (US). LU, Jirong [CN/US]; 6332 Vancouver Court, Indianapolis, IN 46326 (US).

(74) Agents: COLLIER, Kenneth, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

With amended claims.

(54) Title: FSH AND FSH VARIANT FORMULATIONS, PRODUCTS AND METHODS

(57) Abstract

This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, *inter alia*, the invention fills the need for convenient products of FSH or from a FSH variant.